beta-alanine has been researched along with Guillain-Barre Syndrome in 1 studies
Guillain-Barre Syndrome: An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, ZY | 1 |
| Zhang, Z | 1 |
| Zug, C | 1 |
| Nuesslein-Hildesheim, B | 1 |
| Leppert, D | 1 |
| Schluesener, HJ | 1 |
1 other study available for beta-alanine and Guillain-Barre Syndrome
| Article | Year |
|---|---|
AUY954, a selective S1P(1) modulator, prevents experimental autoimmune neuritis.
Topics: Animals; B-Lymphocytes; beta-Alanine; Chemotaxis, Leukocyte; Disease Models, Animal; Guillain-Barre | 2009 |